Clinical trials: Botulinum Toxin, Type A
Overactive Bladder Syndrome, Urinary Urge Incontinence
Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial
Overactive bladder is a common condition that causes sudden urges to urinate, frequent urination, night-time urination, and sometimes leakage of urine.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Detrusor Overactivity
- Trial name
- NCT07184307
- Testing
- Platelet-Rich Plasma, Intravesical Botulinum Toxin Injection
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Benha University
Refractory Migraine
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.
- Trial name
- NCT00660192
- Testing
- Botox
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Myofascial Trigger Point Pain, Myofascial Pain Syndrome
Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome
Evaluating myofascial pain dysfunction symptoms using acupuncture, dry needle and Botox injection using electromyography and visual Analogue Scale on two time intervals at 2 and 6 months after the intervention
- Trial name
- NCT06013644
- Testing
- Acupuncture needle, Dry needle, Botox Injectable Product
- Where
- Egypt
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Cairo University
Cerebral Palsy, Muscle Spasticity
Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
In Norway, about 60% of all children with cerebral palsy (CP) are being treated with botulinum toxin A (BoNT-A) at 6 years of age, mainly in the legs.
- Trial name
- WE (NCT02546999)
- Testing
- botox
- Where
- 7 sites in France, Norway and 1 more
- Volunteers
- 61 people
- Sponsor
- St. Olavs Hospital
Overactive Bladder Syndrome, Refractory Overactive Bladder
Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections
The goal of this clinical trial is to compare the effectiveness and safety of two treatments for refractory overactive bladder in adult women.
- Trial name
- SBD-BOT-OAB (NCT06796855)
- Testing
- Selective Bladder Denervation via Radiofrequency Ablation, Intravesical Onabotulinum Toxin A Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Bagcilar Training and Research Hospital
Plantar Fasciitis
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for injection versus placebo for the management of Plantar…
- Trial name
- NCT03825315
- Testing
- DAXI 80 U, DAXI 120 U
- Where
- 20 sites in United States
- Volunteers
- 155 people
- Sponsor
- Revance Therapeutics, Inc.
N/A, as no Specific Medical Condition Will be Treated
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different…
- Trial name
- NCT05585398
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Masseter Muscle Prominence
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a…
- Trial name
- MMP EU P3 (NCT06068855)
- Testing
- BOTOX
- Where
- 27 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 249 people
- Sponsor
- AbbVie
Cervical Dystonia
A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia
1. to examine the non-inferiority of Dysport in the clinical efficacy and safety in comparison with Botox®, assuming a bioequivalence ratio of 2.5:1 units, in the treatment of Cervical dystonia. 2.
- Trial name
- NCT00950664
- Testing
- Dysport® (abobotulinumtoxinA), Botox® (onabotulinumtoxinA)
- Where
- 7 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Seoul National University Hospital
Migraine, Chronic Migraine Headache
The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- NorMig (NCT07040813)
- Testing
- CGRP mAbs and onabotulinumtoxin A
- Where
- 6 sites in Norway
- Volunteers
- 450 people
- Sponsor
- Oslo University Hospital
Bladder Pain Syndrome
Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A
The purpose of this research study is to evaluate the efficacy of intravesical botulinum A toxin and DMSO in women with bladder pain syndrome who have not responded to first-line treatments.
- Trial name
- NCT03103594
- Testing
- DMSO, Botox
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014622
- Testing
- Botulinum Toxins, Type A
- Where
- 15 sites in United States
- Volunteers
- 303 people
- Sponsor
- Revance Therapeutics, Inc.
Overactive Bladder, Urinary Urgency
Optimal Injection Interval for Intra-Detrusor Botulinum Toxin
The goal of this clinical trial is to see if patients deciding their own follow up times can increase the effectiveness of botulinum toxin (BTX or "Botox") injection for overactive bladder (OAB).
- Conditions
- Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
- Trial name
- NCT06483217
- Testing
- Patient-directed follow up
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Neurogenic Bladder Disorder
Predictive Urodynamic Parameters for The Treatment Efficacy of Onabotulinum A Toxin in Neurogenic Lower Urinary Tract Dysfunction
Purpose: To evaluate urodynamic parameters predicting the treatment efficacy of onabotulinumtoxin A (onaBoNT-A) in patients with neurogenic lower urinary tract dysfunction (NLUTD).
- Trial name
- NCT06485453
- Testing
- Botox 200 UNT Injection
- Volunteers
- 74 people
- Sponsor
- University of Gaziantep
Scar
Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection
Linear hypertrophic scar is a common surgical problem that can be difficult to manage, especially for the median sternotomy scar.
- Trial name
- NCT02886988
- Testing
- Botulinum toxin type A, normal saline
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Xijing Hospital
Urinary Incontinence, Urge
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
The purpose of this randomized, open-label, active-control trial is to compare the effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral neuromodulation (InterStim®, Medtronic) for the treatment of…
- Trial name
- ROSETTA (NCT01502956)
- Testing
- InterStim® device, Botox® injection
- Where
- 9 sites in United States
- Volunteers
- 386 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Shoulder Pain
The Treatment of Shoulder Pain in Hemiplegic Spastic Patients With Botulinum Toxin A
Stroke is the leading cause of disability in developed countries, and the major cause of mortality in Brazil.It is associated with low quality of life, disability, decreased muscle strength and control due to the hypertonia…
- Trial name
- dolomtox (NCT04470401)
- Testing
- AbobotulinumtoxinA, Saline
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- Faculdade de Ciências Médicas da Santa Casa de São Paulo
Post-Operative Atrial Fibrillation
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of…
- Trial name
- NCT03779841
- Testing
- AGN-151607
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 323 people
- Sponsor
- AbbVie
Interstitial Cystitis
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
To evaluate the efficacy and safety of intravesical instillation of Lipotoxin for the treatment of IC/BPS
- Trial name
- NCT02247557
- Testing
- Liposome encapsulated BoNT-A, BOTOX 200U in normal saline, Normal saline
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Spasticity, Post-Stroke
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity.
- Trial name
- NCT03261167
- Testing
- Botulinum toxin A (GSK1358820)
- Where
- 38 sites in Japan
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline